Caxton Associates (New York)’s Merck MRK Stock Holding History

Caxton Associates (New York)’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-35,632	Closed	-$2.62M	–	556
2021 Q1	$2.62M	Buy	+35,632	New	+$2.63M	0.24%	37

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caxton Associates (New York)'s MRK Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Merck (MRK) in Q4 2024, closing a stake of 16,890 shares — an estimated $1.92M sold.

Caxton Associates (New York) first reported a position in MRK in Q2 2013 and held it in 15 quarters. The position peaked at $2.86M in Q2 2024. 3,608 funds tracked by Wall St. Rank hold MRK as of Q4 2024.

Caxton Associates (New York) reported no remaining Merck position as of Q4 2024 after selling out during the quarter.
Caxton Associates (New York) sold 16,890 Merck shares in Q4 2024, an estimated $1.92M.
Caxton Associates (New York) first reported a position in Merck in Q2 2013 and held it in 15 quarters.
Caxton Associates (New York)'s Merck position peaked at $2.86M in Q2 2024.
3,608 funds tracked by Wall St. Rank held Merck as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.